$VIRX
Viracta Therapeutics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021004118 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.015M $3.711M $3.871M
YoY Change 12.78% 59.96% 87.91%
% of Gross Profit
Research & Development $7.303M $7.088M $5.446M
YoY Change 242.86% 128.28% 62.04%
% of Gross Profit
Depreciation & Amortization $59.00K $52.00K $47.00K
YoY Change
% of Gross Profit
Operating Expenses $11.32M $14.80M $9.317M
YoY Change 98.91% 270.72% 119.74%
Operating Profit -$14.80M -$9.317M
YoY Change 270.72% 119.74%
Interest Expense -$129.0K $125.0K $122.0K
YoY Change 89.39% 87.69%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Pretax Income -$11.45M -$14.91M -$9.170M
YoY Change 137.98% 221.42% 43.51%
Income Tax
% Of Pretax Income
Net Earnings -$11.45M -$14.91M -$9.170M
YoY Change 137.98% 265.63% 116.48%
Net Earnings / Revenue
Basic Earnings Per Share -$0.40
Diluted Earnings Per Share -$305.3K -$399.3K -$246.4K
COMMON SHARES
Basic Shares Outstanding 37.31M 37.23M 37.04M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $103.6M $111.0M $122.7M
YoY Change 407.62% 326.86% 593.34%
Cash & Equivalents $103.6M $111.0M $122.7M
Short-Term Investments
Other Short-Term Assets $1.719M $2.032M $2.421M
YoY Change 1.12% 27.0% -66.38%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $105.3M $113.0M $125.1M
YoY Change 123.04% 309.12% 402.58%
LONG-TERM ASSETS
Property, Plant & Equipment $242.0K $258.0K $41.00K
YoY Change 450.0% -35.5% -91.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.397M $2.538M $2.680M
YoY Change 3053.95% 2691.67%
Total Long-Term Assets $3.279M $3.525M $3.537M
YoY Change 196.47% 761.86% 483.66%
TOTAL ASSETS
Total Short-Term Assets $105.3M $113.0M $125.1M
Total Long-Term Assets $3.279M $3.525M $3.537M
Total Assets $108.6M $116.5M $128.7M
YoY Change 124.72% 315.72% 404.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.901M $2.098M $2.566M
YoY Change 86.32% 1298.67% 467.7%
Accrued Expenses $5.802M $4.693M $3.196M
YoY Change 72.58% 38.03% -8.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $833.0K
YoY Change -100.0% -84.85%
Total Short-Term Liabilities $9.084M $7.161M $6.953M
YoY Change 44.56% 100.76% -26.03%
LONG-TERM LIABILITIES
Long-Term Debt $4.819M $5.026M $4.155M
YoY Change 15.98%
Other Long-Term Liabilities $278.0K $378.0K $474.0K
YoY Change
Total Long-Term Liabilities $4.819M $5.026M $4.155M
YoY Change 15.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.084M $7.161M $6.953M
Total Long-Term Liabilities $4.819M $5.026M $4.155M
Total Liabilities $13.90M $12.19M $11.11M
YoY Change 33.18% 241.66% 18.17%
SHAREHOLDERS EQUITY
Retained Earnings -$165.7M -$154.2M -$139.3M
YoY Change 225.4% -77.96% -79.96%
Common Stock $4.000K $4.000K $4.000K
YoY Change 300.0% 100.0% -63.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $94.37M $104.0M $117.1M
YoY Change
Total Liabilities & Shareholders Equity $108.6M $116.5M $128.7M
YoY Change 124.72% 315.72% 404.5%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$11.45M -$14.91M -$9.170M
YoY Change 137.98% 265.63% 116.48%
Depreciation, Depletion And Amortization $59.00K $52.00K $47.00K
YoY Change
Cash From Operating Activities -$7.211M -$7.598M -$6.592M
YoY Change 27.4% 79.2% 13.66%
INVESTING ACTIVITIES
Capital Expenditures -$19.00K -$228.0K -$5.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$4.000M $3.000K
YoY Change -99.91%
Cash From Investing Activities -$19.00K -$4.228M -$2.000K
YoY Change -100.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -199.0K 88.00K 136.0K
YoY Change -1095.0% -98.77% 580.0%
NET CHANGE
Cash From Operating Activities -7.211M -7.598M -6.592M
Cash From Investing Activities -19.00K -4.228M -2.000K
Cash From Financing Activities -199.0K 88.00K 136.0K
Net Change In Cash -7.429M -11.74M -6.458M
YoY Change 31.72% -504.76% 177.17%
FREE CASH FLOW
Cash From Operating Activities -$7.211M -$7.598M -$6.592M
Capital Expenditures -$19.00K -$228.0K -$5.000K
Free Cash Flow -$7.192M -$7.370M -$6.587M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001061027
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-51531
dei Entity Registrant Name
EntityRegistrantName
VIRACTA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3295878
dei Entity Address Address Line1
EntityAddressAddressLine1
2533 S. Coast Hwy. 101, Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Cardiff
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92007
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
400-8470
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
VIRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37311690
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110983000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47089000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2032000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
110000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
113015000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
47199000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
258000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
729000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
986000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2538000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
76000
CY2021Q3 us-gaap Assets
Assets
116540000
CY2020Q4 us-gaap Assets
Assets
48305000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2098000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1557000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4693000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3362000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
370000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
334000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1031000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7161000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6284000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5026000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4155000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
378000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
658000
CY2021Q3 virx Preferred Stocks Warrant Liability Noncurrent
PreferredStocksWarrantLiabilityNoncurrent
0
CY2020Q4 virx Preferred Stocks Warrant Liability Noncurrent
PreferredStocksWarrantLiabilityNoncurrent
106000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10248
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10248
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
5452000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37281226
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37281226
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
905987
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
905987
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
252749000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4714000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-154230000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50915000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
103975000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-46200000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
116540000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48305000
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7088000
CY2020Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3105000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
16558000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9912000
CY2021Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
4000000
CY2020Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
88478000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3711000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
887000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11422000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2777000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
14799000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
3992000
us-gaap Operating Expenses
OperatingExpenses
116458000
us-gaap Operating Expenses
OperatingExpenses
12689000
CY2021Q3 virx Gain Loss On Royalty Purchase Agreement Non Operating
GainLossOnRoyaltyPurchaseAgreementNonOperating
0
CY2020Q3 virx Gain Loss On Royalty Purchase Agreement Non Operating
GainLossOnRoyaltyPurchaseAgreementNonOperating
0
virx Gain Loss On Royalty Purchase Agreement Non Operating
GainLossOnRoyaltyPurchaseAgreementNonOperating
13500000
virx Gain Loss On Royalty Purchase Agreement Non Operating
GainLossOnRoyaltyPurchaseAgreementNonOperating
0
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14799000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3992000
us-gaap Operating Income Loss
OperatingIncomeLoss
-102958000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12689000
CY2021Q3 virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
0
CY2020Q3 virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
0
virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
257000
virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
0
CY2021Q3 us-gaap Interest Income Other
InterestIncomeOther
10000
CY2020Q3 us-gaap Interest Income Other
InterestIncomeOther
1000
us-gaap Interest Income Other
InterestIncomeOther
28000
us-gaap Interest Income Other
InterestIncomeOther
45000
CY2021Q3 us-gaap Interest Expense
InterestExpense
125000
CY2020Q3 us-gaap Interest Expense
InterestExpense
66000
us-gaap Interest Expense
InterestExpense
352000
us-gaap Interest Expense
InterestExpense
66000
CY2021Q3 us-gaap Other Expenses
OtherExpenses
0
CY2020Q3 us-gaap Other Expenses
OtherExpenses
22000
us-gaap Other Expenses
OtherExpenses
290000
us-gaap Other Expenses
OtherExpenses
22000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-115000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-87000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-357000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-43000
CY2021Q3 virx Net Loss And Comprehensive Loss
NetLossAndComprehensiveLoss
-14914000
CY2020Q3 virx Net Loss And Comprehensive Loss
NetLossAndComprehensiveLoss
-4079000
virx Net Loss And Comprehensive Loss
NetLossAndComprehensiveLoss
-103315000
virx Net Loss And Comprehensive Loss
NetLossAndComprehensiveLoss
-12732000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-14.22
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.44
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-46.27
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37353418
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
286833
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29995784
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
275204
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-46200000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
1000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
62317000
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
97982000
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
83302000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
396000
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
5452000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
644000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-79231000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
124744000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
136000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
1000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1386000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-9170000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
117097000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
87000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
1000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1704000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-14914000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
103975000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-28383000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
1000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
86000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4417000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-32713000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
1000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
69000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4236000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-36869000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33000
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
1000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
100000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4079000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-40814000
us-gaap Net Income Loss
NetIncomeLoss
-103315000
us-gaap Net Income Loss
NetIncomeLoss
-12732000
virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
257000
virx Gain On Forgiveness Of Ppp Loan
GainOnForgivenessOfPppLoan
0
virx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
84478000
virx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0
virx Purchased In Process Research And Development
PurchasedInProcessResearchAndDevelopment
4000000
virx Purchased In Process Research And Development
PurchasedInProcessResearchAndDevelopment
0
us-gaap Share Based Compensation
ShareBasedCompensation
3734000
us-gaap Share Based Compensation
ShareBasedCompensation
255000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
119000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15000
virx Change In Fair Value Of Preferred Stock Warrant Liability
ChangeInFairValueOfPreferredStockWarrantLiability
290000
virx Change In Fair Value Of Preferred Stock Warrant Liability
ChangeInFairValueOfPreferredStockWarrantLiability
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1359000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
35000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-743000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
17000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
118000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
303000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-203000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
697000
virx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
12000
virx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
1000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11906000
us-gaap Interest Paid Net
InterestPaidNet
257000
us-gaap Interest Paid Net
InterestPaidNet
30000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1106000
virx Debt Conversion Converted Instrument Warrants Issued Value
DebtConversionConvertedInstrumentWarrantsIssuedValue
0
virx Debt Conversion Converted Instrument Warrants Issued Value
DebtConversionConvertedInstrumentWarrantsIssuedValue
94000
virx Warrant Liability Reclassification To Equity
WarrantLiabilityReclassificationToEquity
396000
virx Warrant Liability Reclassification To Equity
WarrantLiabilityReclassificationToEquity
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11640000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11513000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
233000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
4000000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
17143000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12910000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
5210000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62320000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
304000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62624000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5256000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
63894000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6312000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47089000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18218000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110983000
virx Issuance Of Convertible Preferred Stock Noncash Transaction Upon Merger
IssuanceOfConvertiblePreferredStockNoncashTransactionUponMerger
5452000
virx Issuance Of Convertible Preferred Stock Noncash Transaction Upon Merger
IssuanceOfConvertiblePreferredStockNoncashTransactionUponMerger
0
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
83302000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
virx Issuance Of Common Stock Noncash Transaction Upon Merger
IssuanceOfCommonStockNoncashTransactionUponMerger
97982000
virx Issuance Of Common Stock Noncash Transaction Upon Merger
IssuanceOfCommonStockNoncashTransactionUponMerger
0
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1119
CY2021Q3 virx Percentage Of Outstanding Common Stock Of Combined Company
PercentageOfOutstandingCommonStockOfCombinedCompany
0.86
CY2021Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
65000000.0
CY2021Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
3.5-for-one
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-154200000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111000000.0
CY2021Q3 virx Working Capital
WorkingCapital
105900000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span></p>
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5177848
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13360202
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1507000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1501000
CY2021Q3 virx Accrued Clinical Trial And Contract Expenses
AccruedClinicalTrialAndContractExpenses
2609000
CY2020Q4 virx Accrued Clinical Trial And Contract Expenses
AccruedClinicalTrialAndContractExpenses
1095000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
182000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
716000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
395000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
50000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4693000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3362000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1723000
CY2021Q3 virx Long Term Debt Maturities Repayments Of Principal After Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearThree
3303000
CY2021Q3 virx Aggregate Minimum Payments Under Debt Arrangements
AggregateMinimumPaymentsUnderDebtArrangements
5026000
us-gaap Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Combination1
BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1
103400000
CY2021Q3 us-gaap Business Acquisition Cost Of Acquired Entity Transaction Costs
BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
1600000
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
18956000
CY2021Q3 virx Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Acquired Ipr And D Projects
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredIprAndDProjects
84478000
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
103434000
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
17143000
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
3768000
CY2021Q3 virx Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable And Accrued Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedLiabilities
1955000
CY2021Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
18956000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37281226
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
905987
CY2020Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
18811552
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10248
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6572757
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
21264567
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1704000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3734000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
255000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1128000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.08
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
3087000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.96
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
265000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
35000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.37
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3915000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
852000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
852000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P3Y7M6D
CY2021Q3 virx Fair Value Of Shares Issuable Under Employee Stock Purchase Plan
FairValueOfSharesIssuableUnderEmployeeStockPurchasePlan
25000
CY2020Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
option for an additional year
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
103000
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
86000
us-gaap Operating Lease Expense
OperatingLeaseExpense
504000
us-gaap Operating Lease Expense
OperatingLeaseExpense
194000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
748000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
378000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
729000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
304000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
77000
us-gaap Operating Lease Payments
OperatingLeasePayments
648000
us-gaap Operating Lease Payments
OperatingLeasePayments
239000
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D

Files In Submission

Name View Source Status
0000950170-21-004118-index-headers.html Edgar Link pending
0000950170-21-004118-index.html Edgar Link pending
0000950170-21-004118.txt Edgar Link pending
0000950170-21-004118-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
virx-20210930.htm Edgar Link pending
virx-20210930.xsd Edgar Link pending
virx-20210930_cal.xml Edgar Link unprocessable
virx-20210930_def.xml Edgar Link unprocessable
virx-20210930_htm.xml Edgar Link completed
virx-20210930_lab.xml Edgar Link unprocessable
virx-20210930_pre.xml Edgar Link unprocessable
virx-ex10_2.htm Edgar Link pending
virx-ex31_1.htm Edgar Link pending
virx-ex31_2.htm Edgar Link pending
virx-ex32_1.htm Edgar Link pending
virx-ex32_2.htm Edgar Link pending